Table 2 Risk of thyroid disorders among head and neck cancer patients who received various surgical procedures stratified by primary tumor site
All neck cancers | Oral cancer | Salivary gland cancer | Oropharyngeal, hypopharyngeal, and pharyngeal cancer | Cancers in unspecified sites | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
PTE + ND (N = 7460) | PTE (N = 3730) | PTE + ND (N = 3530) | PTE (N = 1237) | PTE + ND (N = 85) | PTE (N = 453) | PTE + ND (N = 413) | PTE (N = 596) | PTE + ND (N = 3422) | PTE (N = 1444) | |
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Thyroid disorders | 122 (1.64) | 50 (1.34) | 65 (1.84) | 20 (1.62) | 1 (1.18) | 8 (1.77) | 22 (5.33) | 10 (1.68) | 34 (0.99) | 12 (0.83) |
Crude HR | 1.16 (0.83–1.61) | 1 | 1.15 (0.70–1.90) | 1 | 0.74 (0.09–5.94) | 1 | 1.59 (0.75–3.36) | 1 | 1.19 (0.62–2.30) | 1 |
Adjusted HR | 1.21 (0.87–1.68) | 1 | 1.08 (0.65–1.78) | 1 | 0.69 (0.09–5.52) | 1 | 1.50 (0.67–3.38) | 1 | 1.22 (0.63–2.35) | 1 |
CRR | 1.25 (0.90–1.74) | 1 | 1.10 (0.67–1.82) | 1 | 0.66 (0.08–5.23) | 1 | 2.81 (1.37–5.75)* | 1 | 1.17 (0.61–2.27) | 1 |